The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Asfotase alfa therapy for children with hypophosphatasia
Open accessAbstract
Background. Hypophosphatasia (HPP) is caused by loss-of-function mutation(s) of the gene that encodes the tissue-nonspecific isoenzyme of alkaline phosphatase (TNSALP). Consequently, cell-surface deficiency of TNSALP phosphohydrolase activity leads to extracellular accumulation of inorganic pyrophosphate, a natural substrate of TNSALP and inhibitor of mineralization. Children with HPP can manifest rickets, skeletal pain, deformity, fracture, muscle weakness, and premature deciduous tooth loss. Asfotase alfa is a recombinant, bone-targeted, human TNSALP injected s.c. to treat HPP. In 2012, we detailed the 1-year efficacy of asfotase alfa therapy for the life-threatening perinatal and infantile forms of HPP. Methods. Here, we evaluated the efficacy and safety of asfotase alfa treatment administered to children 6–12 years of age at baseline who were substantially impaired by HPP. Two radiographic scales quantitated HPP skeletal disease, including comparisons to serial radiographs from similarly affected historical control patients. Results. Twelve children receiving treatment were studied for 5 years. The 6-month primary endpoint was met, showing significant radiographic improvement. Additional significant improvements included patient growth, strength, motor function, agility, and quality of life, which for most patients meant achieving normal values for age- and sex-matched peers that were sustained at 5 years of treatment. For most, pain and disability resolved. Mild to moderate injection-site reactions were common and were sometimes associated with lipohypertrophy. Low anti–asfotase alfa antibody titers were noted in all patients. No evidence emerged for clinically important ectopic calcification or treatment resistance. Conclusions. Asfotase alfa enzyme replacement therapy has substantial and sustained efficacy with a good safety profile for children suffering from HPP. Trial Registration. ClinicalTrials.gov NCT00952484 (https://clinicaltrials.gov/ct2/show/NCT00952484) and NCT01203826 (https://clinicaltrials.gov/ct2/show/NCT01203826). Funding. Alexion Pharmaceuticals Inc. and Shriners Hospitals for Children.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measurement of health status in children with juvenile rheumatoid arthritis
Singh, G., Athreya, B. H., Fries, J. F., & Goldsmith, D. P. (1994) · Arthritis & Rheumatism · doi:10.1002/art.1780371209 · Cited by 838
Mammalian Alkaline Phosphatases: From Biology to Applications in Medicine and Biotechnology
Millán, J. L. (2006) · doi:10.1002/3527608060 · Cited by 421
Review of the Bruininks-Oseretsky Test of Motor Proficiency, Second Edition (BOT-2)
Deitz, J. C., Kartin, D., & Kopp, K. (2007) · Physical & Occupational Therapy In Pediatrics · doi:10.1080/j006v27n04_06 · Cited by 407 · cited 6×
“Secondary endpoint assessments included changes in TNSALP substrate levels (i.e., plasma PPi and PLP); growth (i.e., height, weight, and BMI Z scores); strength of muscle groups that move the hips and knees, measured using a hand-held dynamometer (21); walking ability and endurance/speed, using a 6MWT (22); physical f…”
BackgroundMethodInfluential
Cited by
Alkaline Phosphatase and Hypophosphatasia
Millán, J. L., & Whyte, M. P. (2016) · Calcified Tissue International · doi:10.1007/s00223-015-0079-1 · Cited by 397
Self-citationDental outcomes for children receiving asfotase alfa for hypophosphatasia
Schroth, R. J., Long, C., Lee, V. H. K., Alai-Towfigh, H., & Rockman-Greenberg, C. (2021) · Bone · doi:10.1016/j.bone.2021.116089 · Cited by 29
Metadata
- Authors
- Whyte, M. P., Madson, K. L., Phillips, D., Reeves, A. L., McAlister, W. H., Yakimoski, A., Mack, K. E., Hamilton, K., Kagan, K., Fujita, K. P., Thompson, D. D., Moseley, S., Odrljin, T., & Rockman-Greenberg, C.
- Venue
- JCI Insight
- Published
- 2016-06-16
- Volume
- 1
- Issue
- 9
- Pages
- e85971-e85971
- ISSN
- 2379-3708 (ISSN-L)
- OpenAlex
- W2437385547
- Cited by
- 174
- References
- 3
- FWCI
- 18.47
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Asfotase alfa therapy for children with hypophosphatasia. https://app.cochat.ai/papers/10.1172/jci.insight.85971
- The paper
- Whyte, M. P., Madson, K. L., Phillips, D., Reeves, A. L., McAlister, W. H., Yakimoski, A., Mack, K. E., Hamilton, K., Kagan, K., Fujita, K. P., Thompson, D. D., Moseley, S., Odrljin, T., & Rockman-Greenberg, C. (2016). Asfotase alfa therapy for children with hypophosphatasia. JCI Insight. https://doi.org/10.1172/jci.insight.85971
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.